Skip to main content

NEW YORK (TheStreet) -- Shares of Celgene Corp. (CELG) are dropping by 4.03% to $101.72 late Wednesday afternoon, ahead of the company's 2015 fourth quarter earnings results due out on Thursday before the market open.

The Summit, NJ-based biopharmaceutical company has been forecasted by analysts surveyed by Thomson Reuters to report earnings of $1.22 per share on revenue of $2.54 billion.

During the same quarter last year, Celgene earned 74 cents per diluted share on revenue of $2 billion.

Together with its subsidiaries, the company is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

Separately, TheStreet Ratings Team has a "buy" rating with a score of B on the stock.

This is driven by several positive factors, which should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks covered by the team.

The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and expanding profit margins. The team feels its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: CELG

Image placeholder title


data by